NVDAMillionaire
Posted - 2 days ago
$BPMC Blueprint Medicines Corporation (BPMC): Transforming Rare Disease Treatment with Innovative Therapies https://beyondspx.com/article/blueprint-medicines-corporation-a-precision-therapy-leader-poised-for-continued-growth
anachartanalyst
Posted - 6 days ago
$BPMC
https://anachart.com/wp-content/uploads/ana_temp/1731668486_soc-img.jpg
IN0V8
Posted - 6 days ago
$BPMC Opportunity JP Morgan initiates coverage with overweight rating JP Morgan initiates coverage with target price $126
Quantumup
Posted - 1 week ago
JPMorgan🏁 $BPMC OW/$126. JPM thinks MGMT's $2B peak sales🎯for AYVAKIT® could prove 2b conservative vs its ests of $2.9B /consensus' est of $2.7B—believes the franchise is not yet fully reflected in shr price—believes $BPMC could be seen as an attractive🎯 for strategic P'ships:
NoRisksNoFun
Posted - 1 week ago
$LEGN $BPMC $TGTX $AXSM l Gens bulls are in despair! Rollercoaster!
swingingtech
Posted - 2 weeks ago
$SATS $RXST $BPMC
https://wallstreetwaves.com/noteworthy-monday-option-activity-sats-rxst-bpmc/
Robcat
Posted - 2 weeks ago
$BPMC Sold my BPMC to get ready to add more $VKTX.
Rolex53
Posted - 2 weeks ago
$BPMC Long due for rally.
NoRisksNoFun
Posted - 2 weeks ago
$MDGL yup, Like $BPMC or $AUPH Never ending story
BioTrade2
Posted - 10/31/24
$BPMC anyone with access to this? I want to see which companies she mentions. https://x.com/MaverickNY/status/1852102989189611742
IN0V8
Posted - 10/31/24
$BPMC Leerink Partners cuts target price to $89 from $97 Needham raises target price to $135 from $133
Quantumup
Posted - 10/30/24
Stifel reiterated $BPMC Buy/$155—thinks shrs set⬆️well from here w/ an Ayvakit growth rate that plausibly puts sales on the path2 MGMTs peak🎯of >$2B, which alone supports⬆️side2the valuation/the oral wtKIT BLU-808 pipeline expansion📗=early-'25 w/ healthy volunteer safety/biomarker🔬:
killbilltrader
Posted - 10/29/24
$BPMC please report great numbers and go back to $100 tomorrow. Wish revenue to be above 150M and raise the guidance for rest of the year.
AivelX
Posted - 10/29/24
💡 #AivelX Premarket Earnings Insights (2/5) 🧵 Earnings breakdown for: BIIB, BPMC, CAT, COCO $BIIB - Ref.Earnings: 159 Gap Up Prob.: 45%, max 20.7%, min -31.7%, avg -1.9% Avg Low vs Open: -5.6% Avg Close vs Low: 3.6% Avg Low-High %: 9.2% 5 Days Later: 55% new highs, 71% new lows Earnings Day: 2% broke 193.8 (+5.2%) $BPMC - Ref.Earnings: 15 Gap Up Prob.: 60%, max 4.1%, min -2.3%, avg 0.2% Avg Low vs Open: -3.2% Avg Close vs Low: 2.2% Avg Low-High %: 5.3% 5 Days Later: 60% new highs, 53% new lows Earnings Day: 20% broke 84.5 (+2.7%) $CAT - Ref.Earnings: 1452 Gap Up Prob.: 44%, max 6.8%, min -19.9%, avg -0.6% Avg Low vs Open: -2.8% Avg Close vs Low: 1.5% Avg Low-High %: 4.1% 5 Days Later: 61% new highs, 59% new lows Earnings Day: 36% broke 373 (-3.8%) $COCO - Ref.Earnings: 47 Gap Up Prob.: 60%, max 10.5%, min -2.5%, avg 0.9% Avg Low vs Open: -1.2% Avg Close vs Low: 2.4% Avg Low-High %: 3.8% 5 Days Later: 64% new highs, 68% new lows Earnings Day: 48% broke 30 (-2%)
Night_Owl_Biotech
Posted - 10/28/24
Our records indicate 7 commercial-stage biopharmas beat analyst consensus revenue estimates by more than 15% in both Q1 & Q2 2024. Attached you will note Q1, Q2 & Q3 revenue data & graphs of their share prices year to date. Q3 estimates are per Seeking Alpha as of 10/28/24. So far, $DCTH is the only one of the 7 commercial-stage bios to beat analyst estimates by more than 15% for all 3 quarters year-to-date. DCTH has not released official Q3 2024 financials yet but did disclose preliminary Q3 2024 revenues early. Of course others may or may not follow including $TARS $BPMC $TGTX. $ESPR revenues include significant non-product revenues (collaboration). Some graphs (SWTX) speak for themselves. We'd highlight SWTX if we did not post about them so much already. This is not investment advice. All bios noted on the attachment have only 1 FDA approved therapy/API (excl BPMC) & therefore could go bankrupt if their product was taken off the market.
NoRisksNoFun
Posted - 10/28/24
$BPMC looks like we leaked and it is bad
Estimize
Posted - 10/28/24
Wall St is expecting 125.38% YoY revenue growth for $BPMC in Q3, down from 140.06% in Q2 [Reporting 10/30 BMO]
http://www.estimize.com/intr
NoRisksNoFun
Posted - 10/25/24
$BPMC sold $IBRX and bought blueprint!
knowthyself
Posted - 10/24/24
$BPMC Anyone have any idea what's going on with this one? Anything negative? If not, it seems overly positive: a BO.
swingingtech
Posted - 1 month ago
$INSM $ORA $BPMC
https://wallstreetwaves.com/significant-friday-options-trading-insm-ora-bpmc-insights/
CH_Expat
Posted - 1 month ago
$BPMC Haunts me until today. Could be retired now, still selling medical devices instead.
Night_Owl_Biotech
Posted - 1 month ago
The attachment compares $IOVA valuation v analyst consensus revenue estimates (per Seeking Alpha & Fintel) to 2 recent commercial-stage oncology focused M&A transactions (IMGN & ARIA). IMGN & ARIA revenue forecasts were prepared by the acquiree's mgmt & are, more or less, in the same ballpark as IOVA analyst estimates. This is not investment advice but does offer a perspective on IOVA's hypothetical M&A valuation. If you believe IOVA analyst revenue estimate per Fintel are credible & if you believe & are good IOVA peers & if you believe an acquirer would pay IMGN & ARIA like multiples to acquire IOVA (THESE ARE 3 HUGE IFS) then IOVA shareholders could do very well should IOVA be acquired. However, if you believe IOVA analyst estimates are overstated then IOVA may not do very well in a hypothetical M&A transaction. We have no idea if IOVA will ever be acquired. We will compare $BPMC & $INCY to peer M&A next. $DCTH also appears very interesting. $XBI
insiderbuyingselling
Posted - 1 month ago
$BPMC new insider selling: 3633 shares. http://insiderbuyingselling.com/?t=BPMC
RonIsWrong
Posted - 09/24/24
$BPMC lowest short interest in at least a year...
